China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Hong Kong Democratic Party Disbands After Member Vote Amid Security Crackdown 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Ukraine’s NATO Concession Unlikely to Shift Peace Talks, Experts Say 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Preservation Group Sues Trump Administration to Halt $300 Million White House Ballroom Project 
Bolivia Orders Pre-Trial Detention of Former President Luis Arce Over Embezzlement Probe 
Belarus Pledges to Halt Smuggling Balloons Into Lithuania 
New Epstein Photos Surface Showing Trump as Lawmakers Near Document Release Deadline 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Trump Signals Two Final Candidates for Fed Chair, Calls for Presidential Input on Interest Rates 
Zelenskiy Signals Willingness to Drop NATO Bid as Ukraine, U.S. Hold Crucial Peace Talks in Berlin 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
